Fig. 2
From: Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases
Boxplot of adalimumab minimal concentrations (Cmin) in children with PRD with and without methotrexate co-treatment. Legend: Adalimumab Cmin concentrations collected 10–14 days after adalimumab administration in pediatric patients with rheumatic diseases in study group A-M (adalimumab and methotrexate treatment) and study group A (adalimumab alone); t-test of log transformed Cmin p = 0.3. The box of the boxplot limits the interquartile ranges (IQR)